These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8674002)

  • 21. [Serum HER-2 determination using a centauer HER-2/neu kit (CLIA method) in metastatic breast cancer].
    Kan N; Yoshikawa S
    Gan To Kagaku Ryoho; 2009 May; 36(5):779-83. PubMed ID: 19461177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma].
    Yu FZ; Sugano K; Ohkura H; Mori S
    Rinsho Byori; 1991 Oct; 39(10):1087-92. PubMed ID: 1684826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
    Meenakshi A; Kumar RS; Kumar NS
    J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
    Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.
    Bewick M; Conlon M; Gerard S; Lee H; Parissenti AM; Zhang L; Glück S; Lafrenie RM
    Bone Marrow Transplant; 2001 Apr; 27(8):847-53. PubMed ID: 11477443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum c-erbB-2 protein in breast cancer patients.
    Chearskul S; Sinlarat P; Bhothisuwan K; Churintrapun M; Ornrhebroi S; Klinsala N; Sungkabunchoo S
    J Med Assoc Thai; 2000 Aug; 83(8):886-93. PubMed ID: 10998842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
    Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
    Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [An investigation of extracellular HER-2/NEU domain level in blood serum from breast cancer patients].
    Korytova LI; Masliukova EA; Ovchinnikov IV; Filipenko MO; Korytov OV; Kudaĭbergenova AG
    Vopr Onkol; 2010; 56(1):62-5. PubMed ID: 20361618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Muñoz M; Farrus B; Latre ML; Gimenez N; Hage M; Estape J; Ballesta AM
    Anticancer Res; 1996; 16(4B):2295-300. PubMed ID: 8694559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.
    Kuerer HM; Thompson PA; Krishnamurthy S; Fritsche HA; Marcy SM; Babiera GV; Singletary SE; Cristofanilli M; Sneige N; Hunt KK
    Clin Cancer Res; 2003 Feb; 9(2):601-5. PubMed ID: 12576424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
    Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
    Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
    Sikic BI; Scudder SA; Ballon SC; Soriero OM; Christman JE; Suey L; Ehsan MN; Brandt AE; Evans TL
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):26-32. PubMed ID: 3099393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer: what's HER-2/neu got to do with it?
    Lenahan C; Dennis C; Isakovich NV; Pories SE
    Curr Surg; 2005; 62(5):459-64. PubMed ID: 16125599
    [No Abstract]   [Full Text] [Related]  

  • 37. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
    Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
    J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
    Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
    Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acute phase proteins in female patients with breast carcinoma].
    Tesarová P; Kvasnicka J; Umlaufová A; Homolková J; Kalousová M; Tesar V
    Sb Lek; 2003; 104(2):121-32. PubMed ID: 14577123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.